Back to journals
Academic Journal

Nature

10 Papers Indexed in Blossom

Data updated

Research Footprint

Nature has 10 tracked papers indexed in Blossom (2016–2024) from 123 authors, most often covering Ketamine, MDMA and Psilocybin, across Depressive Disorders, Substance Use Disorders (SUD) and Medicinal Chemistry & Drug Development.

Published Papers

Open Accessindividual

Psilocybin desynchronizes brain networks

Using dense longitudinal fMRI mapping, a single high dose of psilocybin massively desynchronised cortical and subcortical functional connectivity—dissolving within-network correlations and between-network anticorrelations—far more than methylphenidate and with the strongest effect in the default mode network. These acute changes tracked subjective experience, were attenuated by a perceptual task, and included a persistent reduction in anterior hippocampus–DMN coupling lasting weeks that may underlie psilocybin’s proplasticity and therapeutic effects.

Published
Journal
Nature
Authors
Nicol, G. E.
Paywallindividual

Structural pharmacology and therapeutic potential of 5-methoxytryptamines

This molecular study investigates the underpinnings of 5-MeO-DMT pharmacology and its therapeutic potential through cryogenic electron microscopy structures of 5-HT1A, medicinal chemistry, receptor mutagenesis, and mouse behaviour. The research characterizes molecular determinants of 5-HT1A signalling potency, efficacy, and selectivity, contrasting the structural interactions and pharmacology of 5-MeO-DMT with LSD and clinically used 5-HT1A agonists.

Published
Journal
Nature
Authors
Warren, A. L., Lankri, D., Cunningham, M. J., Serrano, I. C., Parise, L. F., Kruegel, A. C., Duggan, P., Zilberg, G., Capper, M. J., Havel, V., Russo, S. J., Sames, D., Wacker, D.
Open Accessindividual

Psychedelics reopen the social reward learning critical period

This mice study shows that psychedelics (including ketamine & MDMA) open a social reward learning critical period. The duration of the drugs' effects in humans is proportional to the time it takes for the critical period to reopen. Additionally, the restoration of oxytocin-mediated long-term depression in the nucleus accumbens is associated with the reinstatement of social reward learning in adulthood. The study also found that reorganising the extracellular matrix is a common mechanism underlying the critical period reopening caused by psychedelic drugs.

Published
Journal
Nature
Authors
Nardou, R., Sawyer, E., Song, Y. J., Wilkinson, M., Padovan-Hernandez, Y., de Deus, J. L., Wright, N., Lama, C., Faltin, S., Goff, L. A., Stein-O'Brien, G. L., Dölen, G.
Open Accessindividual

Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity

This chemistry paper (2022) simulates the docking of 75 million molecules (tetrahydropyridines, THP) on the serotonin 2a (5-HT2a) receptor. The initial screening led to 17 molecules that were further refined down to two molecules ((R)-69 & (R)-70). These two had antidepressant effects (in mice) but didn't show (acute) psychoactive activity (head-twitch response, change in movement).

Published
Journal
Nature
Authors
Kaplan, A. L., Confair, D. N., Kim, K., Barros-Álvarez, X., Rodriguiz, R. M., Yang, Y., Kweon, O. S., Che, T., Mccorvy, J. D., Kamber, D. N., Phelan, J. P., Martins, L. C., Pogorelov, V. M., Diberto, J. F., Slocum, S. T., Huang, X. P., Kumar, J. M., Robertson, M. J., Panova, O., Seven, A. B., Wetsel, A. Q., Wetsel, W. C., Irwin, J. J., Skiniotis, G., Shoichet, B. K., Roth, B. L., Ellman, J. A.
Paywallindividual

Dual action of ketamine confines addiction liability

This study in mice shows that ketamine does increase dopamine levels in the brain (nucleus accumbens) but doesn't lead to synaptic plasticity (e.g. as seen with cocaine). Thus, the addiction liability of ketamine is (relatively) limited (not taking into account social factors).

Published
Journal
Nature
Authors
Simmler, L. D., Li, Y., Hadjas, L. C., Hiver, A., Van Zessen, R., Lüscher, C.
Paywallindividual

A non-hallucinogenic psychedelic analogue with therapeutic potential

This paper describes an analogue to ibogaine (tabernanthalog) with similar therapeutic potential that is non-toxic, and non-psychedelic.

Published
Journal
Nature
Authors
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., Mccarroll, M. N., Taylor, J. C., Myers-Turnbull, D., Liu, T., Yaghoobi, B., Laskowski, L. J., Anderson, E. I., Zhang, G., Viswanathan, J., Brown, B. M., Tjia, M., Dunlap, L. E., Rabow, Z. T., Fiehn, O., Wulff, H., Mccorvy, J. D., Lein, P. J., Kokel, D., Ron, D., Peters, J., Zuo, Y., Olson, D. E.

Quick Facts

Papers Indexed
10
h-Index
1442
Open Access
No
Publisher
Springer Nature
Country
United Kingdom
Website
Visit